Journal of Oncology / 2010 / Article / Fig 3

Review Article

Significance of Circulating Tumor Cells Detected by the CellSearch System in Patients with Metastatic Breast Colorectal and Prostate Cancer

Figure 3

Kaplan Meier Analysis of overall survival. Favorable CTCs are indicated with 1 through 4 and Unfavorable CTCs with 5 through 8. (a) Median overall survival of MBC patients with Favorable CTC after 3–5 Weeks (1) ( 𝑛 = 9 2 ), 6–8 Weeks (2) ( 𝑛 = 7 7 ), 9–14 Weeks (3) ( 𝑛 = 1 0 5 ) and 15–20 Weeks (4) ( 𝑛 = 7 0 ) of treatment median was 21.7, 19.1, 20.8, and 20.1 months, respectively. Median overall survival of MBC patients with Unfavorable CTC after 3–5 Weeks (5) ( 𝑛 = 4 0 ), 6–8 Weeks (6) ( 𝑛 = 2 2 ) 9–14 Weeks (7) ( 𝑛 = 2 4 ), and 15–20 Weeks (8) ( 𝑛 = 1 5 ) of treatment was 6.2, 6.3, 6.4, and 11.3 months, respectively. (b) Median overall survival of MCRC patients with Favorable CTC after 1–2 Weeks (1) ( 𝑛 = 3 1 6 ), 3–5 Weeks (2) ( 𝑛 = 2 9 2 ), 6–12 Weeks (3) ( 𝑛 = 2 8 5 ), and 13–20 Weeks (4) ( 𝑛 = 1 7 2 ) of treatment was 15.7, 16.4, 15.8, and 14.6 months, respectively. Median overall survival of MCRC patients with Unfavorable CTC after 1–2 Weeks (5) ( 𝑛 = 4 1 ) 3–5 Weeks (6) ( 𝑛 = 4 1 ), 6–12 Weeks (7) ( 𝑛 = 2 5 ), and 13–20 Weeks (8) ( 𝑛 = 2 1 ) of treatment median was 6.1, 4.4, 3.3, and 3.3 months, respectively. (c) Median overall survival of MPC patients with Favorable CTC after 2–5 Weeks (1) ( 𝑛 = 1 2 3 ), 6–8 Weeks (2) ( 𝑛 = 1 1 0 ), 9–12 Weeks (3) ( 𝑛 = 1 0 0 ), and 13–20 Weeks (4) ( 𝑛 = 9 9 ) of treatment median was 20.7, 19.9, 19.6, and 19.8 months, respectively. Median overall survival of MPC patients with Unfavorable CTC after 2–5 Weeks (5) ( 𝑛 = 8 0 ), 6–8 Weeks (6) ( 𝑛 = 5 3 ), 9–12 Weeks (7) ( 𝑛 = 4 9 ), and 13–20 Weeks (8) ( 𝑛 = 4 4 ) of treatment was 9.5, 8.5, 7.6, and 6.7 months, respectively. The cutoff value between favorable and unfavorable CTC was β‰₯ 5 CTC/7.5 mL blood for breast and prostate cancer and β‰₯ 3 CTC/7.5 mL blood for prostate cancer.
617421.fig.003a
(a)
617421.fig.003b
(b)
617421.fig.003c
(c)